# Winstrol (Oral)

*Also known as: Stanozolol, Winny*

Oral stanozolol; cutting agent, joint pain common. Simple model — peak calibrated.

## Overview

Winstrol (stanozolol) is an oral DHT derivative, 17-alpha-alkylated with an added pyrazole ring, developed in 1962 and best known as a cutting agent that builds strength without estrogenic water retention. It binds the androgen receptor and, uniquely among oral AAS, lowers SHBG, which raises the free fraction of co-administered hormones (a real interaction risk). It does not aromatize and is not further 5-alpha-reduced. Its 9-hour half-life drives the standard twice-daily split dosing used in research protocols. Hepatotoxicity is rated moderate, so liver enzymes and lipids (HDL/LDL) are the central harm-reduction concerns. Joint pain is also commonly reported because the drug reduces water and synovial lubrication. HPTA suppression is rapid and dose-dependent.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 0.4 days (9 hours)
- **Cmax:** 49.9 ng/dL
- **Bioavailability:** 100%

## Dosing

- **Default dose:** 30 mg
- **Typical range:** 20–50 mg
- **Units:** ng/dL

## Harm reduction

- **Aromatizes:** No
- **DHT derivative:** Yes
- **Hepatotoxicity:** moderate
- **Injection frequency:** Oral, 2×/day

## Detection time (anti-doping)

- **Window:** 21–42 days post-last-dose
- **Target metabolite:** 3′-hydroxystanozolol
- **Assay:** LC-MS/MS
- **Notes:** 3′-hydroxystanozolol-O-glucuronide detectable ~28 days (N-glucuronides). Parent metabolites clear within 3–4 days.

## Source

- **Label:** Llewellyn Anabolics (11th ed.)
- **URL:** https://pubmed.ncbi.nlm.nih.gov/17348894/
- **Notes:** Cmax calibrated to ng/dL serum peak. Stanozolol PK from Llewellyn; oral bioavailability from ChEBI.

---

**Canonical URL:** https://anabolicdex.com/compounds/winstrol-oral
**Plot:** https://anabolicdex.com/plot?compound=winstrol-oral